Clinical evidence
EXPLORE THE SCIENCE BEHIND WHOLOMICS EARLY CANCER DETECTION.
At Wholomics, transparency and scientific rigor are at the core of what we do.
This page is dedicated to showcase the research and clinical studies that drive our technology forward.
Multi Cancer Early Detection - ASCO Annual Meeting 2025
Journal of Clinical Oncology (JCO)
May 2025
Wholomics MCED assay, powered by Wholomics’ proprietary NMR-based molecular signatures, represents a true leap forward in early cancer detection. At the 2025 ASCO Annual Meeting, we presented results from a multi-center study with 1,211 participants, making this one of the most robust evaluations of a functional biomarker approach in early detection to date.
Key Highlights
Relevance
This study marks a milestone in cancer diagnostics — for the first time, a non-DNA based, cost-efficient blood test has demonstrated such high accuracy for Stage I disease across multiple cancers.
Wholomics is now expanding validation in prospective cohorts and working with partners to bring this breakthrough technology into real-world screening programs.
For a detailed insight into our research and findings, we invite you to download the poster published at the ASCO Annual Meeting 2025 in Chicago. This poster encompasses the methodology, results, and implications of our study, highlighting our commitment to combating solid cancers through early detection.
Article Citation
Patrick C. Strasser et al., Performance evaluation of a multi-cancer early detection assay using NMR-based molecular signatures in a multi-center study.. JCO43, e15079-e15079(2025). DOI:10.1200/JCO.2025.43.16_suppl.e15079
Blinded Pancreatic Cancer Early Detection - ASCO Annual Meeting 2024
Journal of Clinical Oncology (JCO)
May 2024
Independent blinded validation of a novel blood-based early pancreatic cancer detection test.
Wholomics pancreatic cancer early detection test was validated in an independent validation cohort. This confirms the clinical accuracy and reliability of Wholomics technology. The groundbreaking results mark a significant advancement in identifying this challenging disease in its earliest stages. This clinical study included around 400 patients with pancreatic cancer, with a focus on early-stage detection, non-cancerous controls harboring common diseases, like diabetes, arthritis, and neurodegenerative diseases as well as patients with precancerous and benign pancreatic conditions.
Key Highlights
Relevance
This study represents a critical step in our efforts to further improve early detection rates for pancreatic cancer, potentially leading to better patient outcomes and survival rates.
For a detailed insight into our research and findings, we invite you to download the poster published at the ASCO Annual Meeting 2024 in Chicago. This poster encompasses the methodology, results, and implications of our study, highlighting our commitment to combating pancreatic cancer through early detection.
Article Citation
Patrick Christian Strasser et al., Independent blinded validation of a novel blood-based early pancreatic cancer detection test. JCO42, 4166-4166(2024). DOI:10.1200/JCO.2024.42.16_suppl.4166
Pancreatic Cancer Early Detection - ASCO GI Symposium 2024
Journal of Clinical Oncology (JCO)
January 2024
A novel early cancer detection approach for pancreatic cancer.
Wholomics pancreatic cancer early detection test was evaluated on a clinical cohort from the UMC Amsterdam. This marks a significant advancement in identifying this challenging disease in its earliest stages. The clinical study included 104 participants, carefully balanced between healthy controls and individuals diagnosed with pancreatic cancer, with a focus on early-stage detection. The study also included patients with precancerous conditions, providing a comprehensive understanding of the disease's progression.
Key Highlights
Relevance
This study represents a critical step in our efforts to improve early detection rates for pancreatic cancer, potentially leading to better patient outcomes and survival rates.
For a detailed insight into our research and findings, we invite you to download the poster we presented at the ASCO GI Symposium 2024 in San Francisco. This poster encompasses the methodology, results, and implications of our study, highlighting our commitment to combating pancreatic cancer through early detection.
Article Citation
Maarten F. Bijlsma et al., A novel early cancer detection approach for pancreatic cancer. JCO42, 613-613(2024). DOI:10.1200/JCO.2024.42.3_suppl.613